Emerging Technology Brief - Combination Products: Biologic/Drug/Device Convergence

AN EMERGING TECHNOLOGY BRIEF FROM THE MaRS VENTURE GROUP

Combination products that converge medical devices with therapeutics and diagnostics are a rapidly growing segment of the health care industry. Skyrocketing drug development costs (new drugs have an average development price of $802M US1), competition from generics, and cost reduction pressures from third party payers are driving many health care companies to direct their growth strategy toward convergence.

This 2006 brief outlines the market drivers, stats, key players, challenges, projected growth as well as additional resources for doing your own research on this market.

Download it now: Combination Products: Biologic/Drug/Device Convergence

• Email Page
• Print Page
• Increase Font
• Decrease Font

MaRS BLOG

• Fail to design = design to fail

See more articles

MaRS FACTS

MaRS was created in 2000 by a group of visionary business and community leaders concerned about Canada’s performance in the innovation economy.